ESMO: Ayala In Shadow Of SpringWorks In Rare Cancer Race
Israeli Biotech’s Stock Down Despite Desmoid Tumor Success
The companies’ respective gamma-secretase inhibitors provided positive data for desmoid tumors at the ESMO congress but SpringWork’s nirogacestat impressed the most.
